1
|
Rodrigues CIS, Ferreira-Filho SR, Moura AFDS, Poli-de-Figueiredo CE, da Silva DR, Polacchini FSG, de Almeida FA, Pinheiro ME, Bezerra R, de Paula RB, Peixoto AJ, Figueiredo AEPL, Feitosa ADM, Machado CA, Amodeo C, Mion D, Muxfeldt ES, da Silva GV, Moura-Neto JA, Pazeli JM, Lotaif LD, Drager LF, Martín LC, Bortolotto LA, Bastos MG, Malachias MVB, Moreira MVPC, Canziani MEF, Miranda RD, Franco RJDS, Pecoits R, Mulinari RA, Elias RM, Barroso WKS, Nadruz W. I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology. J Bras Nefrol 2025; 47:e20240033. [PMID: 40009791 PMCID: PMC11864789 DOI: 10.1590/2175-8239-jbn-2024-0033en] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 08/01/2024] [Indexed: 02/28/2025] Open
Abstract
Hypertension in dialysis patients (HTND) has a high prevalence, affecting at least 80% or more of patients, and its management in the nephrology practice is heterogeneous and often empirical. Knowing how to define, understand the pathophysiology, diagnose, monitor and treat with lifestyle changes, and adjust antihypertensive drugs to achieve the recommended blood pressure (BP) target - to reduce morbidity and mortality - requires specific knowl-edge and approaches within the contexts of hemodialysis (HD) and peritoneal dialysis (PD). This document is the first guideline of the Brazilian Society of Nephrology, developed by the departments of Hypertension and Dialysis. It aims to guide physicians who provide care in dialysis centers on how to manage patients with HTND, in a comprehensive and individualized manner, based on the critical appraisal of the best available scientific evidence. When such evidence is scarce or unavailable, the opinion of specialists should be recommended. The different topics covered include HTND definition (pre-HD BP ≥ 140/90 mmHg and post-HD BP ≥ 130/80 mmHg), epidemiology, and pathophysiology; diagnosis of HTND preferably with BP measurements outside the dialysis setting (BP ≥ 130/80 mmHg); complementary assessment; blood pressure targets; non-pharmacological treatment; use of the most appropriate antihypertensive medications; special situations; and complications of HTND, predominantly cardiovascular ones.
Collapse
Affiliation(s)
- Cibele Isaac Saad Rodrigues
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Pontifícia Universidade Católica de São Paulo, Sorocaba, SP, Brazil
| | | | - Ana Flávia de Souza Moura
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil
| | - Carlos Eduardo Poli-de-Figueiredo
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Dirceu Reis da Silva
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
| | - Fernanda Salomão Gorayeb Polacchini
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Hospital de Base de São José do Rio Preto, São José do Rio Preto, SP, Brazil
| | - Fernando Antônio de Almeida
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Pontifícia Universidade Católica de São Paulo, Sorocaba, SP, Brazil
| | - Maria Eliete Pinheiro
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Universidade Federal de Alagoas, Alagoas, AL, Brazil
| | - Rodrigo Bezerra
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Universidade Federal de Pernambuco, Recife, PE, Brazil
| | - Rogério Baumgratz de Paula
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil
| | | | | | | | - Carlos Alberto Machado
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Secretaria Municipal de Saúde de Campos do Jordão, Campos do Jordão, SP, Brazil
| | - Celso Amodeo
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
| | - Décio Mion
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Universidade de São Paulo, São Paulo, SP, Brazil
| | - Elizabeth Silaid Muxfeldt
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Giovanio Vieira da Silva
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Universidade de São Paulo, São Paulo, SP, Brazil
| | - José Andrade Moura-Neto
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil
| | - José Muniz Pazeli
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Faculdade de Medicina de Barbacena, Barbacena, MG, Brazil
| | - Leda Daud Lotaif
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Hospital do Coração da Associação Beneficente Síria de São Paulo, São Paulo, SP, Brazil
| | - Luciano F. Drager
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Universidade de São Paulo, São Paulo, SP, Brazil
| | - Luis Cuadrado Martín
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Universidade Estadual Paulista, Botucatu, SP, Brazil
| | - Luiz Aparecido Bortolotto
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Universidade de São Paulo, São Paulo, SP, Brazil
| | - Marcus Gomes Bastos
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil
| | | | | | | | - Roberto Dischinger Miranda
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Universidade Federal de São Paulo, São Paulo, SP, Brazil
| | - Roberto Jorge da Silva Franco
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Universidade Estadual Paulista, Botucatu, SP, Brazil
| | - Roberto Pecoits
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil
- Arbor Research Collaborative for Health, Ann Arbor, United States
| | - Rogerio Andrade Mulinari
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Universidade Federal do Paraná, Curitiba, PR, Brazil
| | - Rosilene Motta Elias
- Brazilian Society of Nephrology, São Paulo, SP, Brazil
- Universidade de São Paulo, São Paulo, SP, Brazil
- Universidade Nove de Julho, São Paulo, SP, Brazil
| | - Weimar Kunz Sebba Barroso
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Universidade Federal de Goiás, Goiania, GO, Brazil
| | - Wilson Nadruz
- Brazilian Society of Hypertension, São Paulo, SP, Brazil
- Brazilian Society of Cardiology, São Paulo, SP, Brazil
- Universidade Estadual de Campinas, Campinas, SP, Brazil
| |
Collapse
|
2
|
Lewinski AA, Jazowski SA, Goldstein KM, Whitney C, Bosworth HB, Zullig LL. Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review. PATIENT EDUCATION AND COUNSELING 2022; 105:3381-3388. [PMID: 36002348 PMCID: PMC9675717 DOI: 10.1016/j.pec.2022.08.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 08/01/2022] [Accepted: 08/09/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVE Clinical inertia, the absence of treatment initiation or intensification for patients not achieving evidence-based therapeutic goals, is a primary contributor to poor clinical outcomes. Effectively combating clinical inertia requires coordinated action on the part of multiple representatives including patients, clinicians, health systems, and the pharmaceutical industry. Despite intervention attempts by these representatives, barriers to overcoming clinical inertia in cardiovascular disease (CVD) risk factor control remain. METHODS We conducted a narrative literature review to identify individual-level and multifactorial interventions that have been successful in addressing clinical inertia. RESULTS Effective interventions included dynamic forms of patient and clinician education, monitoring of real-time patient data to facilitate shared decision-making, or a combination of these approaches. Based on findings, we describe three possible multi-level approaches to counter clinical inertia - a collaborative approach to clinician training, use of a population health manager, and use of electronic monitoring and reminder devices. CONCLUSION To reduce clinical inertia and achieve optimal CVD risk factor control, interventions should consider the role of multiple representatives, be feasible for implementation in healthcare systems, and be flexible for an individual patient's adherence needs. PRACTICE IMPLICATIONS Representatives (e.g., patients, clinicians, health systems, and the pharmaceutical industry) could consider approaches to identify and monitor non-adherence to address clinical inertia.
Collapse
Affiliation(s)
- Allison A Lewinski
- Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Attn: HSR&D COIN (558/152), 508 Fulton Street, Durham, NC 27705, USA; Duke University School of Nursing, Box 3322 DUMC, Durham, NC 27710, USA.
| | - Shelley A Jazowski
- Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, 170 Rosenau Hall, CB #7400, 135 Dauer Drive, Chapel Hill, NC 27599‑7400, USA; Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC 27701, USA; Department of Health Policy, Vanderbilt University School of Medicine, 2525 West End Ave, Suite 1200, Nashville, TN 37203, USA.
| | - Karen M Goldstein
- Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Attn: HSR&D COIN (558/152), 508 Fulton Street, Durham, NC 27705, USA; Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, 200 Morris Street, Durham, NC 27701, USA.
| | - Colette Whitney
- Cascades East Family Medicine Residency, Oregon Health & Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA.
| | - Hayden B Bosworth
- Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Attn: HSR&D COIN (558/152), 508 Fulton Street, Durham, NC 27705, USA; Duke University School of Nursing, Box 3322 DUMC, Durham, NC 27710, USA; Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, 170 Rosenau Hall, CB #7400, 135 Dauer Drive, Chapel Hill, NC 27599‑7400, USA; Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC 27701, USA; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, P.O. Box 102508, Durham, NC 27710, USA.
| | - Leah L Zullig
- Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Attn: HSR&D COIN (558/152), 508 Fulton Street, Durham, NC 27705, USA; Department of Population Health Sciences, Duke University School of Medicine, 215 Morris St, Durham, NC 27701, USA.
| |
Collapse
|
3
|
Saposnik G, Maurino J, Sempere AP, Terzaghi MA, Ruff CC, Mamdani M, Tobler PN, Montalban X. Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. Front Neurol 2017; 8:430. [PMID: 28871238 PMCID: PMC5567059 DOI: 10.3389/fneur.2017.00430] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Accepted: 08/08/2017] [Indexed: 11/13/2022] Open
Abstract
Background Physicians often do not initiate or intensify treatments when clearly warranted, a phenomenon known as therapeutic inertia (TI). Limited information is available on educational interventions to ameliorate knowledge-to-action gaps in TI. Objectives To evaluate the feasibility and efficacy of an educational intervention compared to usual care among practicing neurologists caring for patients with multiple sclerosis (MS). Methods We conducted a pilot double-blind, parallel-group, randomized clinical trial. Inclusion criteria included neurologists who are actively involved in managing MS patients. Participants were exposed to 20 simulated case-scenarios (10 cases at baseline, and 10 cases post-randomization to usual care vs. educational intervention) of relapsing–remitting MS with moderate or high risk of disease progression. The educational intervention employed a traffic light system (TLS) to facilitate decisions, allowing participants to easily recognize high-risk scenarios requiring treatment escalation. We also measured differences between blocks to invoke decision fatigue. The control group responded as they would do in their usual clinical practice not exposed to the educational intervention. The primary feasibility outcome was the proportion of participants who completed the study and the proportion of participants who correctly identified a high-risk case-scenario with the “red traffic light.” Secondary outcomes included decision fatigue (defined as an increment of TI in the second block of case-scenarios compared to the first block) and the efficacy of the educational intervention measured as a reduction in TI for MS treatment. Results Of 30 neurologists invited to be part of the study, the participation rate was 83.3% (n = 25). Of the 25 participants, 14 were randomly assigned to the control group and 11 to the intervention group. TI was present in 72.0% of participants in at least one case scenario. For the primary feasibility outcome, the completion rate of the study was 100% (25/25 participants). Overall, 77.4% of participants correctly identified the “red traffic light” for clinical-scenarios with high risk of disease progression. Similarly, 86.4% of participants correctly identified the “yellow traffic light” for cases that would require a reassessment within 6–12 months. For the secondary fatigue outcome, within-group analysis showed a significant increased prevalence of TI in the second block of case-scenarios (decision fatigue) among participants randomized to the control group (TI pre-intervention 57.1% vs. TI post-intervention 71.4%; p = 0.015), but not in the active group (TI pre-intervention 54.6% vs. TI post-intervention 63.6%; p = 0.14). For the efficacy outcome, we found a non-significant reduction in TI for the targeted intervention compared to controls (22.6 vs. 33.9% post-intervention; OR 0.57; 95% CI 0.26–1.22). Conclusion An educational intervention applying the TLS is feasible and shows some promising results in the identification of high-risk scenarios to reduce decision fatigue and TI. Larger studies are needed to determine the efficacy of the proposed educational intervention. Clinical Trial Registration www.ClinicalTrials.gov, identifier NCT03134794.
Collapse
Affiliation(s)
- Gustavo Saposnik
- Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.,Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, Zurich, Switzerland.,Outcomes Research and Decision Neuroscience Unit, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | - Jorge Maurino
- Neuroscience Area, Medical Department, Roche Farma, Madrid, Spain
| | - Angel P Sempere
- Department of Neurology, Hospital General Universitario de Alicante, Alicante, Spain
| | - Maria A Terzaghi
- Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.,Outcomes Research and Decision Neuroscience Unit, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | - Christian C Ruff
- Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, Zurich, Switzerland
| | - Muhammad Mamdani
- Healthcare Analytics Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | - Philippe N Tobler
- Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, Zurich, Switzerland
| | - Xavier Montalban
- Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.,Neurology-Neuroimmunology Department, Neurorehabilitation Unit, Multiple Sclerosis Centre of Catalonia (Cemcat), Barcelona, Spain
| |
Collapse
|